Similar articles

• Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure.

  Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Ng LL, et al. Am Heart J. 2006 Jul;152(1):94-101. doi: 10.1016/j.ahj.2005.09.020. Am Heart J. 2006. PMID: 16824837
• Natriuretic peptide assays revisited: do we need pro-B-type natriuretic peptide?

  Emdin M, Passino C, Clerico A. Emdin M, et al. J Am Coll Cardiol. 2011 Mar 22;57(12):1396-8. doi: 10.1016/j.jacc.2010.09.075. J Am Coll Cardiol. 2011. PMID: 21414537 No abstract available.
• BNP or NTproBNP? A clinician's perspective.

  Steiner J, Guglin M. Steiner J, et al. Int J Cardiol. 2008 Sep 16;129(1):5-14. doi: 10.1016/j.ijcard.2007.12.093. Epub 2008 Apr 18. Int J Cardiol. 2008. PMID: 18378336 Review.
• Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients.

  Romano S, Necozione S, Guarracini L, Fratini S, Cisternino P, di Orio F, Penco M. Romano S, et al. J Cardiovasc Med (Hagerstown). 2009 Mar;10(3):238-44. doi: 10.2459/JCM.0b013e3283212ee0. J Cardiovasc Med (Hagerstown). 2009. PMID: 19262210
• Natriuretic peptides in the diagnosis and management of heart failure.

  Felker GM, Petersen JW, Mark DB. Felker GM, et al. CMAJ. 2006 Sep 12;175(6):611-7. doi: 10.1503/cmaj.060236. CMAJ. 2006. PMID: 16966666 Free PMC article. Review.